All In Biotech

Drug Trial Radar · NCT06245291

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 1, 2024

Primary completion

Aug 1, 2024

Study completion Aug 1, 2024

Sponsor

Lead sponsor
Arbutus Biopharma CorporationIndustry
Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects

Conditions

  • Hepatitis B, Chronic

Interventions

  • ImdusiranDrug

    subcutaneous injection

  • DurvalumabDrug

    intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of imdusiran and durvalumab in NA suppressed CHB subjectsTime frame: Up to 96 weeks

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • Infectious Diseases, AIDS and Clinical Immunology Research Center

    Tbilisi, Georgia

  • LLC "Neolab"

    Tbilisi, Georgia

  • Prince Of Wales Hospital - The Chinese University Of Hong Kong

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska

    Gdansk, Poland

  • ID Clinic Arkadiusz Pisula

    Mysłowice, Poland

  • Punkt Zdrowia Hlebowicz Jakubowski Lekarze Spółka Partnerska

    Wroclaw, Poland

  • Arensia Exploratory Medicine Srl Romania in colaborare cu Institutul National de Boli Infectioase

    Bucharest, Romania

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Chia-yi Christian Hospital

    Chia-Yi City, Taiwan

  • Kaohsiung Medical University Chung-ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Siriraj Hospital

    Bangkok, Thailand

  • The Hiv Netherlands Australia Thailand Research Collaboration

    Bangkok, Thailand

  • Srinagarind Hospital

    Khon Kaen, Thailand

  • Naresuan University Hospital

    Phitsanulok, Thailand

  • Imperial College Hospital

    London, United Kingdom

  • Royal London Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.